Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
It plans to deliver over 300 million doses to the Indian government
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
